Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GTBP

GT Biopharma Inc

0.4250

Jul 10 • 04:00PM ET -0.0222 (-4.96%)

Healthcare Biotechnology USA Nano NASD

Peers: BLRX CYCN ERNA GDTC GNTA ICU INTS MBRX RKTO TOVX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	18.84M
Enterprise Value	9.82M
Income	-58.42M
Sales	0.00M
Book/sh	0.22
Cash/sh	0.20
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1
IPO	Mar 17, 1980

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.97
P/C	2.09
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.90
Current Ratio	3.90
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-14.40
EPS next Y	-0.27
EPS next Q	-0.08
EPS this Y	94.91%
EPS next Y	20.59%
EPS next 5Y	67.47%
EPS past 3/5Y	31.76% 49.68%
Sales past 3/5Y	- -
EPS Y/Y TTM	-152.00%
Sales Y/Y TTM	-
EPS Q/Q	66.39%
Sales Q/Q	-
Earnings	May 18
EPS/Sales Surpr.	0.00% -

Insider Own	68.71%
Insider Trans	0.00%
Inst Own	5.88%
Inst Trans	0.70%
ROA	-754.45%
ROE	-1446.48%
ROIC	-629.74%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.02%
SMA50	0.13%
SMA200	-23.74%
Trades

Shs Outstand	35.18M
Shs Float	13.87M
Short Float	24.69%
Short Ratio	2.32
Short Interest	3.42M
52W High	2.31 -81.60%
52W Low	0.26 62.84%
Volatility	9.26% 10.25%
ATR (14)	0.05
RSI (14)	45.60
Beta	0.87
Rel Volume	0.71
Avg Volume	1.48M
Volume	1,041,099

Perf Week	-9.92%
Perf Month	1.67%
Perf Quarter	8.89%
Perf Half Y	-41.96%
Perf YTD	-45.87%
Perf Year	-81.44%
Perf 3Y	-94.94%
Perf 5Y	-99.90%
Perf 10Y	-100.00%
Recom	1.00
Target Price	3.00
Prev Close	0.45
Price	0.43
Change	-4.96%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-24	Initiated	ROTH MKM	Buy	$11
May-24-21	Initiated	H.C. Wainwright	Buy	$25
Apr-13-21	Initiated	B. Riley Securities	Buy	$21
Mar-17-21	Initiated	ROTH Capital	Buy	$25

Jul-06-26 11:19AM	A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
Jun-30-26 09:00AM	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire) +11.30%
Jun-01-26 08:00AM	GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives (GlobeNewswire) -7.57%
May-29-26 09:00AM	The $13 Million Company Teaching the Immune System to Hunt Cancer (PR Newswire) +7.36%
May-19-26 09:00AM	Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes (PR Newswire) +18.03%
02:22PM	Loading…
May-18-26 02:22PM	B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic (PR Newswire) -7.51%
May-15-26 08:00AM	GT Biopharma Reports First Quarter 2026 Financial Results (GlobeNewswire) -10.25%
May-14-26 08:30AM	GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors (GlobeNewswire) +40.36%
Mar-11-26 07:00AM	GT Biopharma to Participate in the 38th Annual Roth Conference (GlobeNewswire) +5.67%
Mar-02-26 07:00AM	GT Biopharma Reports Full Year 2025 Financial Results (GlobeNewswire)
Feb-17-26 07:30AM	GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference (GlobeNewswire)
Feb-03-26 08:30AM	GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3 (GlobeNewswire)
Jan-16-26 08:00AM	Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape (PR Newswire)
Jan-15-26 08:30AM	GT Biopharma Announces IND Submission for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers (GlobeNewswire) +10.61%
08:01AM	EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment (Benzinga)
07:55AM	Loading…
Dec-19-25 07:55AM	Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines (PR Newswire)
07:44AM	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 (PR Newswire)
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire)
Dec-08-25 04:28PM	Stocks & Markets Podcast: Biotech CEO reveals the science of humane cancer treatment (TheStreet) +6.56%
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire)
Nov-19-25 08:00AM	GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials (ACCESSWIRE)
Nov-14-25 09:00AM	GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +26.14%
Oct-23-25 09:00AM	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies (GlobeNewswire) +8.99%
Oct-17-25 09:50AM	Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation (PR Newswire)
09:00AM	Precision Oncology Approaches Drive $312B Market Transformation (PR Newswire)
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
08:45AM	Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge (PR Newswire)
Oct-08-25 10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire) +43.67%
09:00AM	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies (GlobeNewswire)
08:31AM	EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers (Benzinga)
09:00AM	Loading…
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire) +6.44%
08:00AM	Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms (PR Newswire)
Oct-06-25 09:00AM	GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit (GlobeNewswire) +10.59%
Sep-04-25 07:00AM	GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 04:05PM	GT Biopharma Reports Second Quarter 2025 Financial Results (GlobeNewswire) -13.69% -7.59%
Aug-11-25 07:00AM	GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 (GlobeNewswire)
Jun-13-25 09:00AM	GT Biopharma Appoints New Member to its Board of Directors (GlobeNewswire)
May-19-25 09:00AM	GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals (GlobeNewswire)
May-15-25 09:00AM	GT Biopharma Appoints New Member to its Board of Directors (GlobeNewswire)
May-14-25 07:00AM	GT Biopharma Appoints New Member to its Board of Directors (GlobeNewswire)
Mar-04-25 07:00AM	GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit (GlobeNewswire) -6.44%
Feb-25-25 02:00PM	GT Biopharma Announces Exercise of Warrants (GlobeNewswire) +21.18%
07:00AM	GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement (GlobeNewswire)
Jan-27-25 07:00AM	GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies (GlobeNewswire) -15.70%
Nov-14-24 04:00PM	GT Biopharma Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Sep-26-24 09:15AM	GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference (GlobeNewswire)
Sep-24-24 09:15AM	GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024 (GlobeNewswire)
Aug-14-24 09:54PM	GTBP Stock Earnings: GT Biopharma Reported Results for Q2 2024 (InvestorPlace)
04:05PM	GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-27-24 09:15AM	GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia (GlobeNewswire) -7.08%
May-21-24 09:15AM	GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -28.21%
May-20-24 08:40AM	Why Is GT Biopharma (GTBP) Stock Up 143% Today? (InvestorPlace) +150.00%
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-16-24 10:53AM	GTBP Stock Earnings: GT Biopharma Beats EPS for Q1 2024 (InvestorPlace) +7.21%
May-15-24 05:00PM	GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-26-24 09:53PM	GTBP Stock Earnings: GT Biopharma Beats EPS for Q4 2023 (InvestorPlace)
05:00PM	GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-01-24 11:00AM	GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split (GlobeNewswire) -6.16%
Dec-06-23 09:30AM	Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote FOR All Proposed Items at the Upcoming Special Meeting of Stockholders (GlobeNewswire)
Dec-04-23 09:30AM	GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia (GlobeNewswire) +6.91%
Nov-06-23 09:30AM	GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting (GlobeNewswire)
Nov-01-23 09:00AM	GT Biopharma Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Aug-07-23 09:00AM	GT Biopharma Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 01:25PM	GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023 (GlobeNewswire) -6.43%
May-15-23 05:00PM	GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +5.19%
May-04-23 09:05AM	GT Biopharma Names Charles J. Casamento to the Board of Directors (GlobeNewswire)
Apr-12-23 07:07AM	Daily Vickers Top Buyers & Sellers for 04/12/2023 (Argus Research) -5.79%
Mar-30-23 05:00PM	GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +18.33%
Feb-24-23 09:00AM	GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Feb-02-23 09:46AM	GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities (GlobeNewswire) +5.00%
Dec-30-22 08:00AM	GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market (GlobeNewswire) -8.69%
Dec-14-22 07:30AM	GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer (GlobeNewswire) -6.67%
Dec-12-22 07:30AM	GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 (GlobeNewswire)
Nov-10-22 03:15PM	GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Nov-03-22 09:00AM	GT Biopharma to Present New Data on Novel Dual-Antigen Targeting Approach Against AML at Upcoming 2022 ASH Annual Meeting (GlobeNewswire)
Oct-31-22 05:15PM	GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results and Business Update (GlobeNewswire)
Oct-25-22 02:44PM	GT Biopharma Presents at LD Micro on October 26, 2022 at 4:30 pm PST (Newsfile)
Oct-06-22 08:18AM	GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)
Oct-04-22 04:10PM	GT Biopharma Announces Adjournment of Special Shareholders Meeting (GlobeNewswire)
Sep-12-22 09:34AM	GT Biopharma Poster Presentation and Mini Oral Session at ESMO Congress 2022 Demonstrates GTB-5550 TriKE® Ability to Specifically Target and Efficiently Kill Multiple B7H3+ Solid and Hematologic Malignancies (GlobeNewswire)
Sep-08-22 07:30AM	GT Biopharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference in September (GlobeNewswire) +12.75%
Aug-30-22 06:00PM	GT Biopharma Affirms Manufacturing Timeline For Lead Investigational Asset GTB-3650 (GlobeNewswire)
Aug-11-22 09:35AM	GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update (GlobeNewswire) -9.41%
Jun-10-22 08:00AM	GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress (GlobeNewswire) -5.21%
May-19-22 07:45AM	Will GT Biopharma (NASDAQ:GTBP) Spend Its Cash Wisely? (Simply Wall St.) +5.56%
May-16-22 08:01AM	GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update (GlobeNewswire) +6.74%
May-12-22 08:00AM	GT Biopharma to Participate at H.C. Wainwright Hybrid Global Investment Conference (GlobeNewswire) +5.26%
Apr-11-22 07:30AM	GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022 (GlobeNewswire)
Mar-28-22 04:15PM	GT Biopharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update (PR Newswire) +7.04%
Mar-21-22 07:30AM	GT Biopharma Presents TriKE® Nanobody Pipeline (GTB-5550) Preclinical Multiple Myeloma Proof-of-Concept Data at 2022 EBMT Annual Meeting (PR Newswire)
Mar-09-22 04:24PM	GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022 (PR Newswire) +9.63%
Mar-03-22 07:30AM	GT Biopharma to Participate In-Person at 34th Annual ROTH Conference, March 13-15, 2022 (PR Newswire)
Feb-24-22 07:30AM	GT Biopharma to Present Pre-Clinical Data at Upcoming Medical Conferences (PR Newswire) +12.86%
Feb-18-22 07:30AM	GT Biopharma Appoints Manu Ohri as Chief Financial Officer (PR Newswire) -10.98%
Jan-20-22 07:30AM	GT Biopharma to Present at B. Riley Securities' Virtual Oncology Conference (PR Newswire)
Jan-06-22 04:30PM	GT Biopharma Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +7.74%
Jan-04-22 05:38PM	Silverleafe Capital Partners, LLC Buys Amazon. ... (GuruFocus.com) -5.96%
Dec-08-21 07:30AM	GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021 (PR Newswire)
Nov-30-21 07:30AM	GT Biopharma Abstract on Novel B7-H3 Immune Checkpoint Targeting Broad Spectrum Solid and Hematologic Malignancies Accepted for Presentation at ESMO IO Congress 2021 (PR Newswire)
Nov-24-21 04:05PM	GT BioPharma to Host a Management Update Conference Call (PR Newswire)

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.

PresidentMr. Michael Martin Breen L.L.B.

CFO & SecretaryMr. Alan Louis Urban CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GTBP

GT Biopharma Inc

Upgrade your Finviz experience